Approved
Zepbound® KwikPen
One weekly shot with one pen a month — shipped to your door.
- One weekly shot with one pen a month
- Avg. 20% body weight loss in a year
- Same active ingredient (tirzepatide) as Mounjaro®
- Zepbound contains tirzepatide — the same active ingredient as Mounjaro®.
- FDA-approved for weight loss in adults with obesity, or overweight with a weight-related condition, alongside diet and exercise.
- Now available as a multi-dose KwikPen or as a single-dose autoinjector pen.
- Zepbound KwikPen is shipped directly to you — one weekly shot, one pen per month.
- Clinically shown to support an average of 20% body weight loss in a year.
Two hormones. One powerful injection.
Get started todayOn average, people on Zepbound lose 21% of their weight in a year.
*Based on clinical trial data from Eli Lilly. Individual results vary.
See your potential
How much could you lose?
Current weight
252lbs
You could lose
38lbs
Based on clinical GLP-1 trial averages. Individual results vary.
How it works
The science, simplified.
Tirzepatide works on two hormone pathways at once (GIP and GLP-1), amplifying appetite suppression and metabolic improvements compared to single-pathway medications. Pricing: cash-pay only — starts at $299/mo, then $399–449/mo for higher doses thereafter.*
Disclaimer: Dosage, treatment plan, and pricing will vary based on your individual health profile and the recommendations of your licensed provider. Final pricing and protocol are determined after clinical review. This page is for informational purposes only and is not a substitute for medical advice. See Important Safety Information.